Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study-Reference-Cited by-同舟云学术

Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study

Published:2023-12-28 Issue:8S Volume:22 Page:3785
ISSN:2619-0125
Container-title:Cardiovascular Therapy and Prevention
language:
Short-container-title:Cardiovasc Ther Prev

Author:

Balanova Yu. A.¹^ORCID,Drapkina O. M.¹^ORCID,Kutsenko V. A.²^ORCID,Imaeva A. E.¹^ORCID,Kontsevaya A. V.¹^ORCID,Maksimov S. A.¹^ORCID,Muromtseva G. A.¹^ORCID,Kotova M. B.¹^ORCID,Karamnova N. S.¹^ORCID,Evstifeeva S. E.¹^ORCID,Kapustina A. V.¹^ORCID,Litinskaya O. A.¹^ORCID,Pokrovskaya M. S.¹^ORCID,Filichkina E. M.²^ORCID,Ivlev O. E.¹^ORCID,Gomanova L. I.¹^ORCID,Doludin Yu. V.¹^ORCID,Efimova I. A.¹^ORCID,Borisova A. L.¹^ORCID,Nazarov B. M.³^ORCID,Yarovaya E. B.²^ORCID,Repkina T. V.⁴^ORCID,Gonoshilova T. O.⁴^ORCID,Kudryavtsev A. V.⁵^ORCID,Belova N. I.⁵^ORCID,Shagrov L. L.⁵^ORCID,Samotrueva M. A.⁶^ORCID,Yasenyavskaya A. L.⁶^ORCID,Chernysheva E. N.⁶^ORCID,Glukhovskaya S. V.⁷^ORCID,Levina I. A.⁷^ORCID,Shirshova E. A.⁷^ORCID,Dorzhieva E. B.⁸^ORCID,Urbanova E. Z.⁸^ORCID,Borovkova N. Yu.⁹^ORCID,Kurashin V. K.⁹^ORCID,Tokareva A. S.⁹^ORCID,Ragino Yu. I.¹⁰^ORCID,Simonova G. I.¹⁰^ORCID,Khudyakova A. D.¹⁰^ORCID,Nikulin V. N.¹¹^ORCID,Aslyamov O. R.¹¹^ORCID,Khokhlova G. V.¹¹^ORCID,Solovyova A. V.¹²^ORCID,Rodionov A. A.¹²^ORCID,Kryachkova O. V.¹²^ORCID,Shamurova Yu. Yu.¹³^ORCID,Tantsyreva I. V.¹³^ORCID,Baryshnikova I. N.¹³^ORCID,Ataev M. G.¹⁴^ORCID,Radjabov M. O.¹⁴^ORCID,Isakhanova M. M.¹⁴^ORCID,Umetov M. A.¹⁵^ORCID,Elgarova L. V.¹⁵^ORCID,Khakuasheva I. A.¹⁵^ORCID,Yamashkina E. I.¹⁶^ORCID,Esina M. V.¹⁶^ORCID,Kunyaeva T. A.¹⁷^ORCID,Nikitina A. M.¹⁸,Savvina N. V.¹⁹^ORCID,Spiridonova Yu. E.¹⁸^ORCID,Naumova E. A.²⁰^ORCID,Keskinov A. A.²¹^ORCID,Kashtanova D. A.²¹^ORCID,Yudin V. S.²¹^ORCID,Yudin S. M.²¹^ORCID,Shalnova S. A.¹^ORCID

Affiliation:

1. National Medical Research Center for Therapy and Preventive Medicine

2. National Medical Research Center for Therapy and Preventive Medicine; Lomonosov Moscow State University

3. City Polyclinic № 109

4. Regional Center for Public Health and Medical Prevention

5. Northern State Medical University

6. Astrakhan State Medical University

7. Sverdlovsk Regional Medical College

8. Boyanov Center for Public Health and Medical Prevention

9. Privolzhsky Research Medical University

10. Research Institute of Internal and Preventive Medicine — branch of the Institute of Cytology and Genetics

11. Orenburg Regional Center for Public Health and Medical Prevention

12. Tver State Medical University

13. South Ural State Medical University

14. Abusuev Research Institute of Environmental Medicine, Dagestan State Medical University

15. Berbekov Kabardino-Balkarian State University

16. Ogarev Mordovian State University

17. Ogarev Mordovian State University; Mordovian Republican Central Clinical Hospital

18. Republican Center for Public Health and Medical Prevention

19. Ammosov North-Eastern Federal University

20. Republican Center for Public Health and Medical Prevention, Exercise therapy and Sports Medicine

21. Center for Strategic Planning and Management of Biomedical Health Risks

Abstract

Aim. To study the epidemiological characteristics and changes of hypertension (HTN), as well as factors associated with HTN in the Russian population aged 35-74 years.Material and methods. The Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation-3 (ESSE-RF3) study examined a representative sample of the population aged 35-74 years of 15 Russian regions with a response >70% (n=28611). Modular design questionnaire was used. Blood pressure (BP) was measured twice after a 5-minute rest in a sitting position on the right arm with an Omron blood pressure monitor. There were following criteria for hypertension: systolic blood pressure (SBP) ≥140 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg, and/or antihypertensive therapy. The effectiveness of treatment was considered the proportion (%) of people who achieved target blood pressure values among those being treated, while the control was considered the proportion (%) of patients with a BP <140/90 mm Hg of the total number of hypertensive patients. HTN changes were studied in a single age range of 35-64 years with the inclusion of materials from the ESSE-RF (2012-14) and ESSE-RF2 (2017) studies, carried out using the same methodology as ESSE-RF3. Statistical analysis was carried out using the open-source R 3.6.1 environment. Analysis of the association between factors and a binary variable was performed using logistic regression. The significance level for all tested hypotheses was 0,05.Results. According to ESSE-RF3, the average levels of SBP and DBP in the population were 131,9±18,7 and 84,4±10,9 mm Hg, respectively, while the proportion of those with BP ≥140/90 mm Hg — 38,8% (men: 44,8%, women: 33,9%). Prevalence of hypertension was 53,9% (men: 56,0%, women: 52,1%), awareness — 77,7% (men: 71,5%, women: 82,3%), while the treatment received 63,4%, significantly higher among women than among men: 72,3 vs 53,3%. The effectiveness of treatment was 44,0%, higher among women compared to men (48,2 vs 37,4%). In addition, 27,9% of patients have controlled HTN.Conclusion. The problem of controlled HTN in Russia remains unresolved in the 21st century. The following significant sex differences remain: the prevalence of HTN is higher among men, but awareness of the disease, treatment rate and its effectiveness are lower compared to women.

Publisher

Silicea - Poligraf, LLC

Subject

Cardiology and Cardiovascular Medicine,Education

Reference27 articles.

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants [published correction appears in Lancet. 2022 Feb 5;399(10324):520]. Lancet. 2021;398(10304):957-80. doi:10.1016/S0140-6736(21)01330-1.

2. Şahin B, İlgün G. Risk factors of deaths related to cardiovascular diseases in World Health Organization (WHO) member countries. Health Soc Care Community. 2022;30(1):73-80. doi:10.1111/hsc.13156.

3. Dolgalev IV, Ivanova AYu, Karpov RS. Predictive value of cardiovascular risk factors in the formation of cardiovascular and all-cause mortality: results of a 27-year cohort prospective study. Russian Journal of Cardiology. 2023;28(2):5045. (In Russ.) doi:10.15829/1560-4071-2023-5045.

4. Balanova YuA, Shalnova SA, Kutsenko VA, et al. Contribution of hypertension and other risk factors to survival and mortality in the Russian population. Cardiovascular Therapy and Prevention. 2021;20(5):3003. (In Russ.) doi:10.15829/1728-8800-2021-3003.

5. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis [published correction appears in Lancet. 2021 May 22;397(10288):1884]. Lancet. 2021;397(10285):1625-36. doi:10.1016/S0140-6736(21)00590-0.